Hypofractionated Stereotactic Body Radiotherapy in Low- and Intermediate-risk Prostate Carcinoma

Overview

Journal Radiat Oncol J

Specialty Oncology

Date 2016 Jun 17

PMID 27306777

Citations 5

Authors

Hun Jung Kim

Jeong Hoon Phak

Woo Chul Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Stereotactic body radiotherapy (SBRT) takes advantage of low α/β ratio of prostate cancer to deliver a large dose in few fractions. We examined clinical outcomes of SBRT using CyberKnife for the treatment of low- and intermediate-risk prostate cancer.

Materials And Methods: This study was based on a retrospective analysis of the 33 patients treated with SBRT using CyberKnife for localized prostate cancer (27.3% in low-risk and 72.7% in intermediate-risk). Total dose of 36.25 Gy in 5 fractions of 7.25 Gy were administered. The acute and late toxicities were recorded using the Radiation Therapy Oncology Group scale. Prostate-specific antigen (PSA) response was monitored.

Results: Thirty-three patients with a median 51 months (range, 6 to 71 months) follow-up were analyzed. There was no biochemical failure. Median PSA nadir was 0.27 ng/mL at median 33 months and PSA bounce occurred in 30.3% (n = 10) of patients at median at median 10.5 months after SBRT. No grade 3 acute toxicity was noted. The 18.2% of the patients had acute grade 2 genitourinary (GU) toxicities and 21.2% had acute grade 2 gastrointestinal (GI) toxicities. After follow-up of 2 months, most complications had returned to baseline. There was no grade 3 late GU and GI toxicity.

Conclusion: Our experience with SBRT using CyberKnife in low- and intermediate-risk prostate cancer demonstrates favorable efficacy and toxicity. Further studies with more patients and longer follow-up duration are required.

Citing Articles

Volumetric modulated arc therapy (VMAT): a review of clinical outcomes-what is the clinical evidence for the most effective implementation?.

Hunte S, Clark C, Zyuzikov N, Nisbet A Br J Radiol. 2022; 95(1136):20201289.

PMID: 35616646 PMC: 10162061. DOI: 10.1259/bjr.20201289.

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis.

Darwis N, Oike T, Kubo N, Gondhowiardjo S, Ohno T Cancers (Basel). 2020; 12(8).

PMID: 32764448 PMC: 7465291. DOI: 10.3390/cancers12082180.

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial.

McDonald A, Dobelbower M, Yang E, Clark G, Jacob R, Kim R Adv Radiat Oncol. 2019; 4(1):90-95.

PMID: 30706015 PMC: 6349624. DOI: 10.1016/j.adro.2018.09.007.

Stereotactic Body Radiotherapy for Primary Prostate Cancer.

Kothari G, Loblaw A, Tree A, van As N, Moghanaki D, Lo S Technol Cancer Res Treat. 2018; 17:1533033818789633.

PMID: 30064301 PMC: 6069023. DOI: 10.1177/1533033818789633.

Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 Patients.

Miszczyk L, Namysl Kaletka A, Napieralska A, Wozniak G, Stapor Fudzinska M, Glowacki G Asian Pac J Cancer Prev. 2017; 18(4):1007-1013.

PMID: 28545199 PMC: 5494208. DOI: 10.22034/APJCP.2017.18.4.1007.

References

Katz A, Santoro M, Diblasio F, Ashley R . Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013; 8:118. PMC: 3674983. DOI: 10.1186/1748-717X-8-118. View

Kupelian P, Potters L, Khuntia D, Ciezki J, Reddy C, Reuther A . Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 58(1):25-33. DOI: 10.1016/s0360-3016(03)00784-3. View

DAmico A, Whittington R, Malkowicz S, Cote K, Loffredo M, Schultz D . Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002; 95(2):281-6. DOI: 10.1002/cncr.10657. View

Demanes D, Martinez A, Ghilezan M, Hill D, Schour L, Brandt D . High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 81(5):1286-92. DOI: 10.1016/j.ijrobp.2010.10.015. View

Hoskin P, Motohashi K, Bownes P, Bryant L, Ostler P . High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol. 2007; 84(2):114-20. DOI: 10.1016/j.radonc.2007.04.011. View

Brenner D, Hall E . Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999; 43(5):1095-101. DOI: 10.1016/s0360-3016(98)00438-6. View

Fowler J, Ritter M, Chappell R, Brenner D . What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003; 56(4):1093-104. DOI: 10.1016/s0360-3016(03)00132-9. View

Jung K, Won Y, Kong H, Oh C, Cho H, Lee D . Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47(2):127-41. PMC: 4398120. DOI: 10.4143/crt.2015.060. View

Chen L, Suy S, Uhm S, Oermann E, Ju A, Chen V . Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013; 8:58. PMC: 3610192. DOI: 10.1186/1748-717X-8-58. View

10.

Vu C, Haas J, Katz A, Witten M . Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer. Front Oncol. 2014; 4:8. PMC: 3904182. DOI: 10.3389/fonc.2014.00008. View

11.

Park Y, Choi I, Yoon S, Jang H, Moon H, Hong S . Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer. Prostate Int. 2015; 3(1):6-9. PMC: 4494537. DOI: 10.1016/j.prnil.2015.02.003. View

12.

King C, Brooks J, Gill H, Presti Jr J . Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 82(2):877-82. DOI: 10.1016/j.ijrobp.2010.11.054. View

13.

Mohler J, Kantoff P, Armstrong A, Bahnson R, Cohen M, DAmico A . Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014; 12(5):686-718. DOI: 10.6004/jnccn.2014.0072. View

14.

McBride S, Wong D, J Dombrowski J, Harkins B, Tapella P, Hanscom H . Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2011; 118(15):3681-90. DOI: 10.1002/cncr.26699. View

15.

Lamb D, Denham J, Joseph D, Matthews J, Atkinson C, Spry N . A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial. Int J Radiat Oncol Biol Phys. 2010; 79(2):385-91. DOI: 10.1016/j.ijrobp.2009.10.071. View

16.

Anwar M, Weinberg V, Chang A, Hsu I, Roach 3rd M, Gottschalk A . Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9:42. PMC: 3923240. DOI: 10.1186/1748-717X-9-42. View

17.

Abramowitz M, Li T, Buyyounouski M, Ross E, Uzzo R, Pollack A . The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2007; 112(1):55-60. DOI: 10.1002/cncr.23139. View

18.

Freeman D, King C . Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011; 6:3. PMC: 3022740. DOI: 10.1186/1748-717X-6-3. View

19.

Patel C, Elshaikh M, Angermeier K, Ulchaker J, Klein E, Chehade N . PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology. 2004; 63(1):110-3. DOI: 10.1016/j.urology.2003.08.025. View

20.

Arcangeli G, Saracino B, Gomellini S, Petrongari M, Arcangeli S, Sentinelli S . A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010; 78(1):11-8. DOI: 10.1016/j.ijrobp.2009.07.1691. View